An announcement from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. has released its preliminary financial results for 2024, showing a significant increase in total operating revenue by 58.40% compared to the previous year. However, the company continues to report a net loss, albeit slightly reduced from the previous year. The company’s total assets and owner’s equity have decreased slightly, indicating ongoing financial challenges. Investors are advised to consider these preliminary results with caution as they are unaudited and subject to change in the final annual report.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. It operates in the biotechnology industry, focusing on the development and commercialization of innovative drugs, particularly in the fields of oncology, autoimmune, and ophthalmic diseases.
YTD Price Performance: 27.36%
Average Trading Volume: 1,888,545
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$15.75B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com